Rigel Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RIGL Nasdaq 2836 www.rigel.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rigel Pharmaceuticals, Inc.

Myelodysplastic Syndrome Market Set for Strong Growth During the Forecast Period (2026-2036) as Targeted Therapies and Novel Treatment Approaches Reshape the Landscape | DelveInsight - Sep 15th, 2026 8:31 am
Rigel to Participate in Upcoming September Investor Conferences - Sep 2nd, 2026 6:05 am
Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope - Aug 15th, 2026 11:08 pm
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers - Aug 14th, 2026 3:28 am
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer - Aug 13th, 2026 6:05 am
Rigel (RIGL) Q2 2026 Earnings Call Transcript - Aug 11th, 2026 6:46 pm
Rigel Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Aug 5th, 2026 6:30 am
Rigel Pharmaceuticals Q2 Earnings Call Highlights - Aug 4th, 2026 8:03 pm
Arvinas, Inc. Q2 2026 Earnings Call Summary - Aug 4th, 2026 3:41 pm
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates - Aug 4th, 2026 3:15 pm
Rigel Reports Second Quarter 2026 Financial Results - Aug 4th, 2026 2:01 pm
Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant) - Jul 29th, 2026 2:30 pm
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results - Jul 28th, 2026 6:05 am
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock? - Jul 7th, 2026 6:20 am
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Jul 7th, 2026 6:05 am
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer - Jul 1st, 2026 6:05 am
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant) - Jun 16th, 2026 2:01 pm
Knight Therapeutics Launches Tavalisse in Mexico - May 28th, 2026 5:42 am